RT Journal Article SR Electronic T1 A globally available COVID-19 – Template for clinical imaging studies JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.04.02.20048793 DO 10.1101/2020.04.02.20048793 A1 G.A. Salg A1 M.K. Ganten A1 M. Baumhauer A1 C.P. Heußel A1 J. Kleesiek YR 2020 UL http://medrxiv.org/content/early/2020/04/07/2020.04.02.20048793.abstract AB Background The pandemic spread of COVID-19 has caused worldwide implications on societies and economies. Chest computed tomography (CT) has been found to support both, current diagnostic and disease monitoring. A joint approach to collect, analyze and share clinical and imaging information about COVID-19 in the highest quality possible is urgently needed.Methods An evidence-based reporting template was developed for assessing COVID-19 pneumonia using an FDA-approved medical software. The annotation of qualitative and quantitative findings including radiomics features is performed directly on primary imaging data. For data collection, secondary information from the patient history and clinical data such as symptoms and comorbidities are queried.Results License-royalty free, cloud-based web platform and on-premise deployments are offered. Hospitals can upload, assess, report and if pseudonymized share their COVID-19 cases. The aggregation of radiomics in correlation with rt-PCR, patient history, clinical and radiological findings, systematically documented in a single database, will lead to optimized diagnosis, risk stratification and response evaluation. A customizable analytics dashboard allows the explorative real-time data analysis of imaging features and clinical information.Conclusions The COVID-19-Template is based on a systematic, computer-assisted and context-guided approach to collect, analyze and share data. Epidemiological and clinical studies for therapies and vaccine candidates can be implemented in compliance with high data quality, integrity and traceability.An additional explanation video of the COVID-19-Template video is provided via:http://cloud1.mint-medical.de/downloads/player/index.html?v=Covid19StandardizedAssessmentWebHighlightsDynamic evidence-based electronic case report form (eCRF) for COVID-19 including documentation of primary imaging data, secondary clinical data and patient history including radiomics featuresComputer-assisted, context-guided reporting approach based on FDA approved medical product software package available free of chargeData quality, traceability, integrity in open-access web platformCustomizable analytics dashboard for explorative real-time data analysis of imaging features and clinical informationHuman and machine-readable data export for clinical trialsCompeting Interest StatementG.A.S., M.K.G. disclose consultative activity for Mint Medical GmbH (Heidelberg, Germany), M.B. serves as chief executing officer. Non-commercial research activity, clinical usage and dissemination of data collected and analyzed regarding the COVID-19 pandemic on the mint lesion software platform are free of charge for every non-commercial or clinical user. Mint Medical GmbH refuses any commercial usage of the collected and analyzed data itself. All data will remain property of the participating institution. Pseudonymized data contributed to an open access platform will be available to the public free of charge.Funding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe manuscript itself is a report about a developed tool for collaborational data acquisition using standardized criteria for assessment, reporting and analysis of patients with COVID-19 pneumonia. It does not contain any original data, besides those included in the manuscript.